Gateway to Translation Webinar: Microbiotica Limited
We are excited to announce a new series of webinars developed by Translation Manchester in collaboration with our colleagues at the Cambridge Academy of Therapeutic Sciences (CATS).
Dr Mat Robinson
SVP Research
Microbiotica Limited
The aim of these webinars is to stimulate translation of basic research into the clinics by educating academics about trends, technologies and research in the commercial sphere and by facilitating collaborations between academia and the medtech, biotech and pharma industry sectors.
The second webinar of this series, hosted by CATS, was on 30th April 2024 with guest speaker Dr Mat Robinson, SVP Research at Microbiotica Limited. Seminar Title: “Discovery of microbiome-based therapeutics: A clinic-first approach in IBD and immune-oncology enabled by precision microbiome profiling”.
The webinar was chaired by Dr Virginia Pedicord, group leader at the University of Cambridge.
Click to learn more about Microbiotica
About Microbiotica
Microbiotica is a Cambridgeshire based company, which identifies gut bacteria linked to phenotype with unprecedented precision in order to discover and develop live bacterial therapeutics and biomarkers from clinical datasets.
Initially built out of 10 years investment in the Wellcome Sanger Institute, Microbiotica has unrivalled capabilities in microbiome analysis linked to patient phenotype. It is a global leader in gut bacterial culturing, and has a world leading microbiome Culture Collection, proprietary Reference Genome Database and advanced microbiome bioinformatics. The company also has advanced capabilities in microbiome/host biology and preclinical development of bacterial products.
Microbiotica has a pipeline of highly differentiated clinically-derived products including Live Bacterial Therapeutics and Biomarkers in IBD, Immuno-oncology and Gut Epithelial Barrier Repair.
It has collaborations with MSD (Merck & Co., Inc.), Cancer Research UK and Cambridge University Hospitals in Immuno-oncology, and University of Adelaide in Ulcerative Colitis.
Click to learn more about the Speaker
Matthew Robinson received a PhD in Immunology from University College London and continued academic research with postdoctoral research positions at National Institute of Medical Research and Cancer Research UK. During this time, his research focused on how the interaction between microbes and innate immune cells leads to inflammation and an appropriate adaptive immune response.
Mat worked at MedImmune/AstraZeneca for the next ten years. Initially, he was a Scientist in the Department of Respiratory, Inflammation and Autoimmunity, where he developed an interest in Inflammatory Bowel Disease, before transitioning to immuno-oncology.
Since 2019, Mat has been the VP Translational Biology and then SVP Research at Microbiotica (Cambridge). Here, Mat has helped develop 2 drugs made of commensal bacteria that are about to enter the clinic in immune-oncology and Inflammatory Bowel Disease.
Watch a recording from the event below:
Download slides from the presentation
The “Gateway to Translation” G2T webinar series is a joint initiative between The University of Manchester (Translation Manchester) and University of Cambridge (Cambridge Academy of Therapeutic Sciences, CATS).
The format was established by the Cambridge Academy of Therapeutic Sciences (CATS) and has been running since 2020. Recordings from previous webinars organised by our colleagues at Cambridge are available here. Starting from this year, CATS and Translation Manchester have partnered to run the series jointly on a monthly basis. Videos from previous webinars of this joint series are available here.
Contact Us
Email:
0 Comments